Buy Or Sell Opportunity • May 21
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 1.5% to €14.56. The fair value is estimated to be €11.81, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 22% in the next 2 years. Reported Earnings • May 20
First quarter 2026 earnings released First quarter 2026 results: Revenue: €146.4m (up 3.9% from 1Q 2025). Net income: €20.0m (up 23% from 1Q 2025). Profit margin: 14% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Upcoming Dividend • May 20
Upcoming dividend of €0.25 per share Eligible shareholders must have bought the stock before 25 May 2026. Payment date: 27 May 2026. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (2.8%). Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Giovanna D'Esposito was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Mar 18
EL.En. S.p.A. announces Annual dividend, payable on May 27, 2026 EL.En. S.p.A. announced Annual dividend of EUR 0.2500 per share payable on May 27, 2026, ex-date on May 25, 2026 and record date on May 26, 2026. Aankondiging • Mar 21
EL.En. S.p.A., Annual General Meeting, Apr 29, 2025 EL.En. S.p.A., Annual General Meeting, Apr 29, 2025, at 10:00 W. Europe Standard Time. Aankondiging • Mar 18
EL.En. S.p.A. announces Annual dividend, payable on May 21, 2025 EL.En. S.p.A. announced Annual dividend of EUR 0.2200 per share payable on May 21, 2025, ex-date on May 19, 2025 and record date on May 20, 2025. Reported Earnings • Nov 17
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €154.7m (up 4.2% from 3Q 2023). Net income: €15.3m (up 18% from 3Q 2023). Profit margin: 9.9% (up from 8.8% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €11.64, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.73 per share. Reported Earnings • Sep 13
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €169.3m (down 8.1% from 2Q 2023). Net income: €12.9m (up 41% from 2Q 2023). Profit margin: 7.6% (up from 5.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Buy Or Sell Opportunity • Sep 02
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 5.8% to €10.39. The fair value is estimated to be €8.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 32% in the next 2 years. Buy Or Sell Opportunity • Aug 17
Now 21% overvalued Over the last 90 days, the stock has fallen 5.3% to €9.50. The fair value is estimated to be €7.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 32% in the next 2 years. Valuation Update With 7 Day Price Move • May 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €9.49, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 2.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.76 per share. Reported Earnings • May 17
First quarter 2024 earnings released First quarter 2024 results: EPS: €0.18. Revenue: €153.1m (down 5.1% from 1Q 2023). Net income: €14.4m (down 13% from 1Q 2023). Profit margin: 9.4% (in line with 1Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Upcoming Dividend • May 13
Upcoming dividend of €0.20 per share Eligible shareholders must have bought the stock before 20 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (1.8%). Declared Dividend • Mar 25
Dividend of €0.20 announced Shareholders will receive a dividend of €0.20. Ex-date: 20th May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (33% earnings payout ratio) but not covered by cash flows (131% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to €10.43, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.57 per share. Reported Earnings • Mar 16
Full year 2023 earnings released Full year 2023 results: Revenue: €699.6m (up 3.9% from FY 2022). Net income: €48.2m (down 13% from FY 2022). Profit margin: 6.9% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Oct 19
Non-Executive Director recently bought €113k worth of stock On the 10th of October, Alberto Pecci bought around 13k shares on-market at roughly €8.46 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €261k. Insiders have collectively bought €515k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Oct 08
Non-Executive Director recently bought €261k worth of stock On the 4th of October, Alberto Pecci bought around 31k shares on-market at roughly €8.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €358k more in shares than they have sold in the last 12 months. Reported Earnings • Sep 14
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €184.3m (flat on 2Q 2022). Net income: €9.17m (down 16% from 2Q 2022). Profit margin: 5.0% (down from 6.0% in 2Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 22
Upcoming dividend of €0.22 per share at 1.9% yield Eligible shareholders must have bought the stock before 29 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%). Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €12.44, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.11 per share. Reported Earnings • Mar 17
Full year 2022 earnings released Full year 2022 results: Revenue: €673.6m (up 18% from FY 2021). Net income: €55.1m (up 21% from FY 2021). Profit margin: 8.2% (up from 8.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Independent Board Member Fabia Romagnoli was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Aankondiging • Nov 16
EL.En. S.p.A., Annual General Meeting, Dec 15, 2022 EL.En. S.p.A., Annual General Meeting, Dec 15, 2022, at 10:00 Central European Standard Time. Location: the registered office in Calenzano, Via Baldanzese n. 17 Calenzano Italy Agenda: To report on the 2021-2023 remuneration policy: amendment of the first section of the Report pursuant to art. 123-ter paragraph 3-bis of Legislative Decree 58/1998; to consider the approval pursuant to art. 114-bis of Legislative Decree 58/1998 of the 2026-2031 stock option plan reserved for members of the board of directors, collaborators and employees of the company and its subsidiaries; and to discuss other related matters. Reported Earnings • Sep 14
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €185.6m (up 18% from 2Q 2021). Net income: €10.9m (up 30% from 2Q 2021). Profit margin: 5.9% (up from 5.3% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany. Upcoming Dividend • May 16
Upcoming dividend of €0.20 per share Eligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.2%). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Independent Board Member Fabia Romagnoli was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Apr 07
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 3.9%. The fair value is estimated to be €18.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings is also forecast to grow by 9.6% per annum over the same time period. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: €577.4m (up 42% from FY 2020). Net income: €45.4m (up 124% from FY 2020). Profit margin: 7.9% (up from 5.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 9.3%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • Mar 04
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be €16.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years. Buying Opportunity • Feb 15
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be €15.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years. Buying Opportunity • Jan 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be €16.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years. Reported Earnings • Nov 15
Third quarter 2021 earnings released: EPS €0.17 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €133.1m (up 26% from 3Q 2020). Net income: €13.7m (up 73% from 3Q 2020). Profit margin: 10% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment improved over the past week After last week's 16% share price gain to €16.60, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 42x in the Medical Equipment industry in Germany. Total returns to shareholders of 276% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.77 per share. Reported Earnings • Sep 15
Second quarter 2021 earnings released: EPS €0.10 (vs €0.022 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €157.5m (up 75% from 2Q 2020). Net income: €8.35m (up 394% from 2Q 2020). Profit margin: 5.3% (up from 1.9% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 16% share price gain to €15.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 182% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.42 per share. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment deteriorated over the past week After last week's 72% share price decline to €12.15, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total loss to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.57 per share. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 16% share price gain to €40.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 98% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €39.45 per share. Upcoming Dividend • May 17
Upcoming dividend of €0.40 per share Eligible shareholders must have bought the stock before 24 May 2021. Payment date: 26 May 2021. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.3%). In line with average of industry peers (1.1%). Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 23% share price gain to €35.95, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 50x in the Medical Equipment industry in Germany. Total returns to shareholders of 162% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.22 per share. Reported Earnings • Mar 17
Full year 2020 earnings released The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €413.8m (up 3.0% from FY 2019). Net income: €20.3m (down 22% from FY 2019). Profit margin: 4.9% (down from 6.5% in FY 2019). The decrease in margin was driven by higher expenses. Aankondiging • Mar 17
El.En. S.P.A. Provides Earnings Guidance for the Year 2021 EL.En. S.p.A. provided earnings guidance for the year 2021. For the year, guidance for year 2021 provides for the resumption of the growth path that the pandemic has slowed down without interrupting it. Strong of its operating structures consolidated over time in an organization aimed at the medium-term sustainability of the group's success, the Company expects growth of more than 10% for 2021, with an improvement in the operating result and hopefully also in operating profitability. Aankondiging • Mar 16
EL.En. S.p.A. Proposes to Distribute a Dividend, Payable on May 26, 2021 EL.En. S.p.A. resolved to propose to distribute a dividend of EUR 0.40 per share, in compliance with art. 2357-ter c.c., to be paid on May 26, 2021, to be assigned on May 24, 2021 (coupon no. 5) with record date May 25, 2021. Is New 90 Day High Low • Feb 10
New 90-day high: €28.90 The company is up 30% from its price of €22.20 on 11 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.84 per share. Is New 90 Day High Low • Jan 22
New 90-day high: €28.75 The company is up 31% from its price of €21.90 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.85 per share. Is New 90 Day High Low • Jan 06
New 90-day high: €27.00 The company is up 26% from its price of €21.50 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.05 per share. Is New 90 Day High Low • Dec 10
New 90-day high: €26.65 The company is up 20% from its price of €22.15 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €32.18 per share. Is New 90 Day High Low • Nov 19
New 90-day high: €24.00 The company is up 7.0% from its price of €22.35 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.17 per share. Valuation Update With 7 Day Price Move • Nov 07
Market bids up stock over the past week After last week's 24% share price gain to €21.80, the stock is trading at a trailing P/E ratio of 18.7x, up from the previous P/E ratio of 15.1x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total return to shareholders over the past year is a loss of 18%. Valuation Update With 7 Day Price Move • Oct 29
Market pulls back on stock over the past week After last week's 18% share price decline to €18.10, the stock is trading at a trailing P/E ratio of 16.1x, down from the previous P/E ratio of 19.7x. This compares to an average P/E of 53x in the Medical Equipment industry in Germany. Total return to shareholders over the past year is a loss of 27%. Is New 90 Day High Low • Oct 29
New 90-day low: €18.10 The company is down 19% from its price of €22.35 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.31 per share. 
